Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941236 · ClinicalTrials.gov registry record · Phase 3
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
A Phase 3 study of Congenital Hyperinsulinism, sponsored by Zealand Pharma.
- Active
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
- 10
- Study locations
NCT03941236 is a Phase 3 study of Congenital Hyperinsulinism that is active but no longer recruiting, run by Zealand Pharma. The registered enrollment target is 42 participants, below the 72-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (42% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT03941236, a Phase 3 study of Congenital Hyperinsulinism, is active but no longer recruiting, sponsored by Zealand Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.
Conditions Studied
Interventions
- DRUG dasiglucagon
Study Locations (10)
Other
- University Hospital Düsseldorf, Department of Pediatrics - Düsseldorf
- Otto von Guericke University Magdeburg, Department of Pediatrics - Magdeburg
- Hadassah Medical Center - Jerusalem
- NHS Greater Glasgow and Clyde - Glasgow
- Alder Hey Children's Hospital NHS Foundation Trust - Liverpool
- Great Ormond Street Hospital for Children NHS Foundation Trust - London
- Manchester University NHS Foundation Trust - Manchester
Colorado
- Children's Hospital Colorado - Aurora
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Endocrinology and Diabetes Clinic - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941236
The ClinicalTrials.gov registry entry for NCT03941236 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (42% lower). The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Hyperinsulinism appearing as the primary indexed condition, and to 1 intervention - of which dasiglucagon is the first listed.
NCT03941236 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, Colorado, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03941236 about?
NCT03941236 is a clinical study titled "Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism". This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials). The primary objective is to evaluate the long-term safety of dasiglucagon...
What is the current status of trial NCT03941236?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2019-05-02. Estimated completion is 2026-12-31.
What conditions does trial NCT03941236 study?
This clinical trial studies the following conditions: Congenital Hyperinsulinism.
What interventions are being tested in trial NCT03941236?
The interventions under investigation include: dasiglucagon (DRUG).
Who is sponsoring clinical trial NCT03941236?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03941236 being conducted?
This trial has 10 study locations across Colorado, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Hyperinsulinism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RZ358 Treatment for Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
RECRUITING · Phase 2
-
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
RECRUITING · Phase 2
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
COMPLETED · Phase 2
-
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.